



# The TIMI Trials

## TIMI 10A

**OBJECTIVE:** To evaluate the pharmacokinetics, safety and efficacy of several doses of TNK-tPA among patients presenting with acute ST elevation myocardial infarction.

1. Cannon CP, McCabe CH, Gibson CM, Ghali M, Sequeira RF, McKendall GR, Breed J, Modi NB, Fox NL, Tracy RP, Love TW, Braunwald E. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose- ranging trial. *Circulation* 1997;95:351-6.
2. Rizzo MJ, Cannon CP, McLean C, Martin NE, Mukesh G, Marble SJ, Dodge T, Gibson M, for the TIMI 10A Investigators. Relationship between timing of vessel opening after thrombolysis and flow at 90 minutes. *Circulation* 1996;94[Suppl. I]:I-440.
3. Tanasijevic MJ, Cannon CP, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Antman EM, Braunwald E. Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A. *Am Heart J* 1997;134:622-30.
5. McLean C, Rizzo M, Ryan K, McCabe C, Cannon CP, Gibson M, Braunwald E, for the TIMI 10A Investigators. Predictors of slowed non-culprit blood flow post thrombolysis. *J Am Coll Cardiol* 1997;29 (Suppl. A):131A.
6. Rizzo M, Dotani I, McLean C, Ryan K, McCabe CH, Tanasijevic M, Cannon C, Gibson M, Braunwald E, for the TIMI 10A Trialists. Persistent myoglobin elevation is associated with slower flow in patent culprit arteries following successful thrombolysis. *J Am Coll Cardiol* 1997;29 (Suppl. A):132A.
4. Modi NB, Eppler S, Breed J, Cannon CP, Braunwald E, Love TW. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction. *Thromb Haemost* 1998;79:134-9.